REFERENCES
  1. Ju H, Jones M, Mishra G. The prevalence and Risk Factors of Dysmenorrhea. Epidemiol Rev 2014;36 (1):104-113.
  2. Allen WM, Masters WH. Traumatic laceration of uterine support. Am J Obstet Gynecol. 1955;70:500-13.
  3. Cagnacci A, Grandi G, Cannoletta, Xholli A, Piacenti I, Volpe A. Intensity of menstrual pain and estimated angle of uterine flexion. Acta Obstet Gynecol Scand 2014 Jan;93(1):58-63.
  1. Hammoud A, Gago LA, Diamond MP. Adhesions in patients with Chronic Pelvic pain : a role for adhesiolysis? Fertil Steril 2004 Dec;82(6):1483-91.
  2. Chan WY. Prostaglandins and nonsteroidals antiinflammatory drugs in dysmenorrhera. Annu Rev Pharmacol Toxicol 1983;23 :131-149.
  3. Borghi C, Dell’Atti L. Pelvic congestion syndrome : the current state of the literature. Arch Gynecol Obstet 2016 Feb;293(2):291-301.
  4. Petros PE, Richardson PA. TFS posterior sling improves overactive bladder, pelvic pain and abnormal emptying, even with minor prolapse-a prospective urodynamic study. Pelviperineology 2010;29:52-5.
  5. Stratton P, Berkley KJ. Chronic Pelvic Pain and endometriosis: translational evidence of the relationship and implications. Human Reprod Update 2011 May-Jun;17(3):327-46.
  6. López A. Pain and Endometriosis. Convergences PP annual congress; Madrid 2019 November 14-16th.
  7. Woolf CJ. Evidence for a central component of post-injury pain hypersensitivity. Nature 1983;3065944:686-8.
  8. Woolf CJ. Central Sensitization : uncovering the relation between pain and plasticity. Anesthesiology 2007;106(4):864-7.
  9. Woolf CJ. Central Sensitization : Implications for the diagnosis and treatment of pain. Pain 2011 ; 152(suppl 3):S2-15.
  10. Woolf CJ. What to call amplification of nociceptive signals in the central nervous system that contribute to wispread pain. Pain 2014;155(10):1911-2.
  11. Bonaz B. Visceral sensitivity perturbation integration in the brain-gut axis in functional digestive disorders. J Physiol Pharmacol 2003 Dec ;54 Suppl 4:27-42.
  12. Kanazawa M, Hongo M, Fukudo S. Visceral hypersensitivity in irritable bowel syndrome. J Gastroenterol Hepatol 2011 Apr;26 Suppl 3:119-21.
  13. Eisenbruch S. Abdominal pain in irritable bowel syndrome : a review of putative psychological, neural and neuro-immune mechanisms. Brain Behav Immun 2011 Mar;25(3):386-94.
  14. Keszthelyi D, Troost FJ, Simrén M, Ludidi S, Kruimel JW, Conchillo Jm et al. Revisiting concepts of visceral nociception in irritable bowel syndrome. Eur J Pain 2012 Nov;16(10):1444-54.
  15. Fitzgerald MP, Koch D, Senka J. Visceral and cutaneous sensory testing in patients with painful bladder syndrome. Neurourol Urodyn 2005;24(7):627-32.
  16. Lai HH, Gardner V, Ness TJ, Gereau RW. Segmental hyperalgesia to mechanical stimulus in interstitial cystitis/bladder pain syndrome : evidence of central sensitization. J Urol 2014 May;191(5):1294-9.
  17. Grundy L, Caldwell A, Brierley SM. Mechanisms underlying overactive bladder and interstitial Cystitis/painful bladder syndrome. Front Neurosci 2018 Dec 12;12:931.
  18. Akiyama Y, Luo Y, Hanno PM, Maeda D, Homma Y. Interstitial cystitis/bladder pain syndrome : The evolving landscape, animal models and future perspectives. Int J Urol 2020 Apr 4. Doi :10.
  19. Iacovides S, Baker FC, Bentley A. Women with dysmenorrhea are hypersensitive to experimental deep muscle pain across the menstrual cycle. J Pain 2013 Oct;14(10):1066-76.
  20. Iacovides S, Avidon I, Baker FC. What we know about primary dysmenorrhea today : a critical review. Hum Reprod Update 2015 Nov-Dec;21(6):762-78.
  21. Giamberardino MA, Tana C, Costantini R. Pain theresholds in women with chronic pelvic pain. Curr Opin Obstet Gynecol 2014 Aug;26(4):253-9.
  22. Jarrell J, Arendt-Nielsen J. Allodynia and dysmenorrhea. J Obstet Gynecol Can 2016 Mar;38(3):270-4.
  23. Jarrell J, Arendt-Nielsen J. Evolutionary considerations in the development of chronic pelvic pain. Am J Obstet Gynecol. 2016 Aug;215(2):201.e1-4.
  24. Katoaka M, Togashi K, Kido A, Fujiwara T, Koyama T, Fujii S. Dysmenorrhea : evaluation with cine-mode-display MR imaging initial experience. Radiology 2005 Apr;235(1):124-31.
  25. Guo SW, Mao X, Ma Q, Liu X. Dysmenorrhea and its severity are associated with increased uterine contractility and overexpression of oxytocin receptor (OTR) in women symptomatic adenomyosis. Fertil Steril 2013 Jan;99(1):231-40.
  26. Liu S, Zhang Q, Yin C, Chan Q, Chen W, He J, Zhu B. Optimized approach to cine MRI of uterine peristalsis. J Magn Reson Imaging 2016 Dec ;44(6) :1397-1404.
  27. Bautrant E, Bryselbout MA, Thiers-Bautrant D, Eggermont E, Boyer R, Cassin H et al. Chronic pelvic pain syndrome due to uterine adenomyosis : diagnostic criteria and conservative treatment. Pelvi Perineol 2011;6:42-45.
  28. Reynolds WS, Dmochowski R, Wein A, Bruehl S. Does central sensitization help explain idiopathic overactive bladder ? Nat Rev Urol 2016 Aug;13(8) :481-91.
  29. Kuo HC, Jiang YH, Tsai YC, Kuo YC. Intravesical botulinum toxin-A injections reduce bladder painof interstitial cystitis/bladder pain syndrome refractory to conventional treatment - A prospective, multicenter, randomized, double-blind, placebo-controlled clinical trial. Neurourol Urodyn 2016 Jun;35(5):609-14.
  30. Giannantoni A, Gubbiotti M, Bini V. Botulinum Neurotoxin A intravesical injections in interstitial cystitis/bladder painful syndrome : A systematic review with meta-analysis. Toxins (Basel) 2019 Sep 30;11(9):510.
  31. Bautrant E, Levêque C, Boyer R, Collet S, Bartoli D, Carbone P. Pilot study of Botulinum Toxin A uterine muscle injection in the the treatment of acute dysmenorrhea, uterine pain and deep dyspareunia. Toxicon 2018;S2-S120:S7-8.
  32. Bautrant E. « Endometriosis like » syndrome : from the concept of uterine pain syndrome to the use of Botulinic Toxin injections. Convergences PP annual congress ; Madrid 2019 November 14-16th.
  33. Levesque A et al, Convergences PP Network. Cinical criteria of central sensitization in chronic pelvic and perineal pain (Convergences PP criteria): elaboration of a clinical evaluation tool based on formal expert consensus. Pain Med 2018;19(10):2009-2015.
  34. Latremoliere A, Woolf CJ. Central sensitization : a generator of pain hypersensitivity by central neural plasticity. J Pain 2009 sep10;(9):895-926.
  35. Pohl M Central nociceptive sensitization : cellular and molecular signalization systems. Douleurs Evaluation-Diagnostic-Traitement 2014;15:44-51.
  36. Sengupta JN. Visceral pain : the neurophysiological mechanism.Handb Exp Pharmacol 2009;194:32-74.
  37. Janig W. Neurobiology of visceral pain. Schmerz 2014 Jun;28(3):233-51.
  38. Zang Z, Cai YQ, Zou F, Bie B, Pan ZZ. Epigenetic suppression of GAD65 expression mediates persistant pain. Nat Med 2011;17:1448-55.
  39. Affaitati G, Costantini R, Tana C, Cipollone F, Giamberardino MA. Co-occurrence of pain syndromes. J Neural Transm (Vienna) 2020 Apr;127(4):625-646
  40. Evans SF, Brooks TA, Esterman AJ, Hull ML, Rolan PE. The comorbidities of dysmenorrhea : a clinical survey comparing symptom profile in woman with and without endometriosis. J Pain Res 2018 Dec 13;11:3181-3194.
  41. Stratton P, Khachikyan I, Sinaii N, Ortiz R, Shah j. Association of chronic pelvic pain and endometriosis with signs of sensitization and myofascial pain. Obstet Gynecol 2015 Mar;125(3):719-28.
  42. Grundström H, Gerdle B, Alehagen S, Berterö C, Arendt-Nielsen L et al. Reduced pain thersholds and signs of sensitization in women with persistent pelvic pain and suspected endometriosis. Acta Obstet Gynecol Scand 2019 Mar;98(3):327-336.
  43. Giamberardino MA, Costantini R, Affaitati G, Fabrizio A, Tafuri E, Mezzetti A. Viscero-visceral hyperalgesia: characterization in different clinical models. Pain 2010 Nov;151(2):307-22.
  44. Bautrant E, O Porta, F Murina, H Mühlrad, C Levêque, T Riant, S Ploteau, G Valancogne, A Levesque. Provoked vulvar vestibulodynia : Epidemiology in Europe, physio-pathology, consensus for first line treatment and evaluation of second-line treatments. J Gynecol Obstet Hum Reprod 2019;48:685-88.
  45. Poulain B. Botulinum neurotoxin. Rev Neurol(Paris). 2010 Jan;166(1):7-20.
  46. Montal M. Botulinum neurotoxin : a marvel of protein design. Annu Rev Biochem 2010;79:591-617.
  47. Pellett S, Yaksh TL, Ramachandran R. Current status and future directions of botulinum neurotoxins for targeting pain processing. Toxins (Basel) 2015;7(11):4519-4563.
  48. Aredo JV, Heyrana KJ, Karp BI, Shah JP, Stratton P. Relating chronic pelvic pain and endometriosis to signs of sensitization and myofascial pain and dysfunction. Semin Reprod Med 2017 Jan;35(1):88-97.
  49. Abbott JA, Jarvis SK, Lyons SD, Thomson A, Vancaille TH. Botulinum toxin type A for chronic pain and pelvic floor spasm in women : a andomized controlled trial. Obstet Gynecol 2006 Oct;108(4):915-23.
  50. Bautrant E, Quintas-Marquès L, Eggermont J, Faller E, Weber P, Poirson E, Boyer R, Carbone P. Use of botulinum toxin neurotoxin type A injections to the perineal muscles in cases of perineal pain and dysfunction associated with pelvic floor muscle overcontraction and myalgia. Toxicon 2014;11:021.
  51. Morrissey D, El-Khawand D, Ginzburg N, Wehbe S, O’Hare P3rd, Whitmore K. Botulinum toxin A injections into pelvic floor muscles under electromyographic guidance for women with refractory high-tone pelvic floor dysfunction : A 6-month prospective pilot study. Female Pelvic Med Reconstr Surg 2015 Sep-Oct;21(5):277-82.
  52. Karp BI, Tandon H, Vigil D, Stratton P. Methodological approaches to botulinum toxin for the treatment of chronic pelvic pain, vaginismus, and vulvar pain disorders. Int Urogynecol J 2019 Jul;30(7):1071-1081.
  53. Tandon HK, Stratton P, Sinaii N, Shah J, Karp BI. Botulinum toxin for chronic pelvic pain in women with endometriosis : a cohort study of a pain-focused treatment. Reg Anesth Pain Med 2019 Jul 8 (ahead of print).
  54. Abbott J. Gynecological indications for the use of botulinum toxin in women with chronic pelvic pain. Toxicon 2009 Oct:54(5):647-53.
  55. Bhide AA, Puccini F, Khullar V, Elneil S, Digesu GA. Botulinum neurotoxin type A injection of the pelvic floor muscle in pain due to spasticity : a review of the current literature. Int Urogynecol J. 2013 Sep;24(9):1429-34.
  56. Dessie SG, Von Bargen E, Hacker MR, Haviland MJ, Elkadry E. A randomized, double blind, placebo-controlled trial of onabotulinumtoxin A trigger point injections for myofascial pelvic pain. Am J Obstet Gynecol 2019 Nov;221(5):517.
  57. Levesque A, Ploteau S, Michel F, Siproudhis L, Bautrant E, Eggermont J, Rabischong B, Volteau C, Perrouin-Verbe MA, Labat JJ. Botulinum toxin infiltrations versus local anaesthetic infiltrations in pelvic floor myofascial pain : Multicentre, randomized, double blind study. Ann Phys Rehabil Med 2020 Jan 22 (ahead of print).
  58. Brin MF, Kirby RS, Slavotinek A, Miller-Messana MA, Parker L et al. Pregnancy outcomes following exposure to onabotulinumtoxinA. Pharmacoepidemiol Drug Saf 2016 Feb;25(2):179-87.
  59. Li W, Tang M. Application of botulinum toxin in pregnancy and its impact in female reproductive health. Expert Opin Drug Saf 2020 Jan;19(1):83-91.
  60. Neblett R, Hartzell MM, Cohen H, Mayer TG, Williams M, Choi Y et al. Ability of the Central Sensitization Inventory to Identify Central Sensitivity Syndromes in an Outpatient Chronic Pain Sample. Clin J Pain 2014;31(4) :323-32.